| GTO ID | GTC2466 |
| Trial ID | NCT04562298 |
| Disease | Epithelial Ovarian Cancer |
| Altered gene | MESO |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | LCAR-M23 |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer |
| Year | 2020 |
| Country | China |
| Company sponsor | Shanghai East Hospital |
| Other ID(s) | BM2L201906 |
| Cohort 1 | |||||||||
|
|||||||||